These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29112446)

  • 1. Relevance of Half-Life in Drug Design.
    Smith DA; Beaumont K; Maurer TS; Di L
    J Med Chem; 2018 May; 61(10):4273-4282. PubMed ID: 29112446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of controlled release delivery systems using a modified pharmacokinetic approach: a case study for drugs having a short elimination half-life and a narrow therapeutic index.
    Sood A; Panchagnula R
    Int J Pharm; 2003 Aug; 261(1-2):27-41. PubMed ID: 12878393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram to predict the best biological half-life values for candidates for oral prolonged-release formulations.
    Zhou M; Notari RE
    J Pharm Sci; 1996 Aug; 85(8):791-5. PubMed ID: 8863265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of long acting propranolol. Implications for therapeutic use.
    Nace GS; Wood AJ
    Clin Pharmacokinet; 1987 Jul; 13(1):51-64. PubMed ID: 3304770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primer on clinical pharmacokinetics.
    Bauer LA
    Am J Hosp Pharm; 1983 Oct; 40(10):1637-41. PubMed ID: 6638025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic parameters: which are necessary to define a drug substance?
    Benet LZ
    Eur J Respir Dis Suppl; 1984; 134():45-61. PubMed ID: 6586486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination half-life of drugs: value and limitations.
    Greenblatt DJ
    Annu Rev Med; 1985; 36():421-7. PubMed ID: 3994325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
    Dutta S; Reed RC
    Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state pharmacokinetics of a novel extended-release metformin formulation.
    Timmins P; Donahue S; Meeker J; Marathe P
    Clin Pharmacokinet; 2005; 44(7):721-9. PubMed ID: 15966755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein binding and drug clearance.
    Rowland M
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():10-7. PubMed ID: 6705422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations.
    Brittain ST; Wheless JW
    Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Criticism of pharmacokinetic clearance concepts.
    Keller F; Schoole J
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):563-8. PubMed ID: 6654532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug dosing in chronic hepatic disease (author's transl)].
    Gugler R; Eichelbaum M
    Leber Magen Darm; 1981 Apr; 11(2):81-7. PubMed ID: 7015045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovations in drug delivery.
    Conrad KA
    Postgrad Med; 1984 Oct; 76(5):71-3, 75-9. PubMed ID: 6483697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms.
    Sahin S; Benet LZ
    Pharm Res; 2008 Dec; 25(12):2869-77. PubMed ID: 19015955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Clearance, Volume of distribution, and Half-life of Drugs in Extremely Low to Low Birth Weight Neonates: An Allometric Approach.
    Mahmood I
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):601-610. PubMed ID: 27562171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Kidney and drugs - urinary lithiasis. Pharmacokinetic glossary].
    Balant L
    Rev Med Suisse Romande; 1980 Nov; 100(11):949-56. PubMed ID: 7466067
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics in renal failure.
    Nancarrow C; Mather LE
    Anaesth Intensive Care; 1983 Nov; 11(4):350-60. PubMed ID: 6359952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics in clinical practice. I. Concepts.
    Gibaldi M; Levy G
    JAMA; 1976 Apr; 235(17):1864-7. PubMed ID: 946488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
    Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.